• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

产碳青霉烯酶肺炎克雷伯菌在接受头孢他啶/阿维巴坦治疗后体内出现头孢地尔和头孢他啶/阿维巴坦交叉耐药性。

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies.

机构信息

Division of Microbiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Clinical Infectious Diseases Unit IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

出版信息

Diagn Microbiol Infect Dis. 2024 Sep;110(1):116372. doi: 10.1016/j.diagmicrobio.2024.116372. Epub 2024 May 21.

DOI:10.1016/j.diagmicrobio.2024.116372
PMID:38875893
Abstract

We described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω-loop. Taken together, our results indicate that prolonged exposure to ceftazidime/avibactam can confer cross-resistance to ceftazidime/avibactam and cefiderocol.

摘要

我们描述了产 KPC 肺炎克雷伯菌感染患者中头孢他啶/阿维巴坦和头孢地尔肟交叉耐药性的出现。所有具有头孢他啶/阿维巴坦和头孢地尔肟交叉耐药性的菌株在 KPC Ω-环上均显示出点突变。综上所述，我们的结果表明，长时间接触头孢他啶/阿维巴坦可导致对头孢他啶/阿维巴坦和头孢地尔肟的交叉耐药性。

相似文献

1
In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies.产碳青霉烯酶肺炎克雷伯菌在接受头孢他啶/阿维巴坦治疗后体内出现头孢地尔和头孢他啶/阿维巴坦交叉耐药性。
Diagn Microbiol Infect Dis. 2024 Sep;110(1):116372. doi: 10.1016/j.diagmicrobio.2024.116372. Epub 2024 May 21.
2
In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.产 KPC 肺炎克雷伯菌感染中新型β-内酰胺/β-内酰胺酶抑制剂合剂耐药性的体内发展：病例系列。
Eur J Clin Microbiol Infect Dis. 2024 Dec;43(12):2407-2417. doi: 10.1007/s10096-024-04958-w. Epub 2024 Oct 10.
3
Complete Genome Sequence of a Strain Carrying Novel Variant , Cross-Resistant to Ceftazidime/Avibactam and Cefiderocol, but Susceptible to Carbapenems, Isolated in Italy, 2023.2023年在意大利分离出的携带新型变体的菌株的全基因组序列，对头孢他啶/阿维巴坦和头孢地尔耐药，但对碳青霉烯类敏感
Pathogens. 2024 Jun 15;13(6):507. doi: 10.3390/pathogens13060507.
4
Concomitant Resistance to Cefiderocol and Ceftazidime/Avibactam in Two Carbapenemase-Producing Isolates from Two Lung Transplant Patients.两例肺移植患者分离的产碳青霉烯酶株对头孢地尔和头孢他啶/阿维巴坦的协同耐药。
Microb Drug Resist. 2024 Jan;30(1):21-26. doi: 10.1089/mdr.2023.0054. Epub 2023 Oct 23.
5
In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.头孢地尔在体外对头孢他啶-阿维巴坦敏感和耐药的产 KPC 肠杆菌科的活性：交叉耐药性和协同作用。
Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):63-70. doi: 10.1007/s10096-021-04341-z. Epub 2021 Aug 31.
6
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
7
Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.体内产 KPC-3 肺炎克雷伯菌出现对头孢他啶/阿维巴坦的耐药性。
J Antimicrob Chemother. 2019 Nov 1;74(11):3211-3216. doi: 10.1093/jac/dkz330.
8
Dynamic evolution of KPC-230-mediated resistance to ceftazidime-avibactam during the treatment of carbapenem-resistant Klebsiella pnenmoniae.碳青霉烯类耐药肺炎克雷伯菌治疗期间KPC-230介导的对头孢他啶-阿维巴坦耐药性的动态演变
Drug Resist Updat. 2025 Mar;79:101205. doi: 10.1016/j.drup.2025.101205. Epub 2025 Jan 25.
9
Adaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producing during antimicrobial chemotherapy.在抗菌化疗期间，流行的产KPC的ST11菌株中广泛耐药性和持续性的适应性进化。
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0123524. doi: 10.1128/aac.01235-24. Epub 2024 Dec 10.
10
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.

引用本文的文献

1
Epidemiology and Genomic Characterization of over a Period of 4 Years in Northern Italy.意大利北部4年期间的流行病学与基因组特征分析
J Fungi (Basel). 2025 Jul 29;11(8):566. doi: 10.3390/jof11080566.
2
Genomic and molecular characterization of a ceftazidime-avibactam resistant Klebsiella pneumoniae strain isolated from a Chinese tertiary hospital.从中国一家三级医院分离出的对头孢他啶-阿维巴坦耐药的肺炎克雷伯菌菌株的基因组和分子特征
BMC Microbiol. 2025 Apr 8;25(1):199. doi: 10.1186/s12866-025-03929-1.
3
Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during exposure to ceftazidime/avibactam in .
在暴露于头孢他啶/阿维巴坦期间导致对头孢洛扎/他唑巴坦和亚胺培南/西司他丁/瑞来巴坦耐药的突变。
Microbiol Spectr. 2025 Mar 4;13(3):e0231224. doi: 10.1128/spectrum.02312-24. Epub 2025 Feb 11.
4
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.头孢地尔的活性、疗效及新出现的耐药机制研究进展
Curr Issues Mol Biol. 2024 Dec 14;46(12):14132-14153. doi: 10.3390/cimb46120846.